Atlas Trials

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Clinical trial NCT07226895 · RECRUITING

Trial details

NCT number
NCT07226895
Sponsor
Monument Therapeutics Limited
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Clinical High Risk for Psychosis (CHR)
Start date
2026-03-03
Primary completion
2027-09-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.